Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Progressive supranuclear palsy (PSP) is a rare, progressive neurodegenerative tauopathy that impairs balance, movement, eye control, and cognition. According to Reema A Sharaf et al., 2024, it affects about 5 to 6 individuals per 100,000 people globally. According to the progressive supranuclear palsy pipeline analysis by Expert Market Research, the drug landscape is expanding with multiple candidates targeting tau pathology and neurodegeneration, spanning Phase II and III development, reflecting a growing focus on disease‑modifying therapies. The growing prevalence, heightened diagnostic recognition, and unmet medical needs are expected to drive pipeline innovation and market growth in the coming years.
-
Major companies involved in the progressive supranuclear palsy pipeline analysis include Amylyx Pharmaceuticals Inc., Ferrer Internacional S.A., and others.
-
Leading drugs currently in the pipeline include AMX0035, FNP-223, UCB0107 (Bepranemab), and others.
-
The pipeline shows significant expansion driven by emerging disease-modifying therapies, increasing clinical trials targeting tau protein, and growing investment in neurodegenerative research, indicating robust development momentum in the coming years.
Report Coverage
The Progressive Supranuclear Palsy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into progressive supranuclear palsy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for progressive supranuclear palsy. The progressive supranuclear palsy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The progressive supranuclear palsy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with progressive supranuclear palsy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to progressive supranuclear palsy.
Read more about this report - Request a Free Sample
Progressive Supranuclear Palsy Pipeline Outlook
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder characterized by impaired balance, gait difficulties, eye movement abnormalities, speech problems, and cognitive decline. It occurs due to abnormal accumulation of tau proteins in specific brain regions, leading to progressive neuronal damage and dysfunction, primarily affecting individuals over 60 years of age.
Progressive supranuclear palsy treatments focus on symptom management and disease modification, including physical therapy, medications for motor and cognitive symptoms, and investigational therapies targeting tau protein accumulation. In June 2025, FNP-223, an orally administered O-GlcNAcase inhibitor, received FDA Fast Track designation for Progressive Supranuclear Palsy. Currently in Phase 2 trials, FNP-223 aims to reduce abnormal tau aggregation, offering a potential disease-modifying therapy for PSP-Richardson syndrome patients.
Progressive Supranuclear Palsy Epidemiology
The pipeline is gaining attention due to the disease’s epidemiology and unmet medical needs. According to Reema A. Sharaf et al., 2024, the disease affects approximately 5 to 6 people per 100,000 population. As per Shashank Agarwal et al., 2023, incidence increases with age, from 1.7 cases per 100,000 at ages 50–59 years to 14.7 per 100,000 at 80–89 years. The mean age of onset is around 65 years, and cases under 40 are extremely rare. Improved recognition of clinical variants is driving research and the development of targeted therapies.
Progressive Supranuclear Palsy – Pipeline Therapeutic Assessment
This section of the report covers the analysis of progressive supranuclear palsy drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The progressive supranuclear palsy pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Progressive Supranuclear Palsy Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total progressive supranuclear palsy clinical trials, with 58%, reflecting significant clinical development and potential near-term therapies. Early phase I represents 17% of the pipeline, while phase I, phase III, and phase IV each represent 8% reflecting later-stage clinical development, supporting innovation and potential expansion of effective progressive supranuclear palsy treatments.
Progressive Supranuclear Palsy Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the progressive supranuclear palsy pipeline analysis include small molecules, monoclonal antibodies, and peptides. The progressive supranuclear palsy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for progressive supranuclear palsy. Peptide-based therapies are gaining attention in the progressive supranuclear palsy market for their potential to modify disease progression. For instance, GV1001, a peptide drug developed by GemVax & KAEL Co., Ltd., is under investigation. Phase 2a trial results demonstrated improvements in PSP-Rating Scale scores and responder rates, supporting further evaluation in Phase 3 studies as a promising therapeutic option.
Progressive Supranuclear Palsy Clinical Trials – Key Players
The EMR report for the progressive supranuclear palsy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed progressive supranuclear palsy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in progressive supranuclear palsy clinical trials:
- Amylyx Pharmaceuticals Inc.
- Ferrer Internacional S.A.
- UCB Biopharma SRL
- Enigma Biomedical
- GemVax & Kael
- C2N Diagnostics
- Life Molecular Imaging GmbH
- Biogen
- Allon Therapeutics
- Novartis Pharmaceuticals
- AbbVie
- Avid Radiopharmaceuticals
Progressive Supranuclear Palsy – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for progressive supranuclear palsy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of progressive supranuclear palsy drug candidates.
Drug: FNP-223
FNP-223, sponsored by Ferrer Internacional S.A., is an orally administered O-GlcNAcase (OGA) inhibitor currently being evaluated in a Phase 2 PROSPER trial for progressive supranuclear palsy (PSP). The study examines the efficacy of FNP-223 in slowing disease progression over 52 weeks using the PSP Rating Scale (PSPRS), while also assessing its safety, tolerability, and pharmacokinetics. Mechanistically, FNP-223 binds to the active site of the OGA enzyme, preventing the removal of O-GlcNAc modifications from tau proteins. This increases glycosylated tau, reducing abnormal tau aggregates and neurofibrillary tangles, potentially slowing neurodegeneration in PSP.
Drug: UCB0107 (Bepranemab)
UCB0107 (Bepranemab) is a monoclonal antibody drug being developed to target progressive supranuclear palsy (PSP). Sponsored by UCB Biopharma SRL, this Phase 1 study is actively examining the long-term safety and tolerability of intravenous administration of Bepranemab in study participants. The drug is delivered as a solution for infusion, allowing direct entry into the bloodstream to reach the brain efficiently. Bepranemab is designed to modulate pathological tau protein aggregation, a key factor in PSP progression. This open-label extension study is continuously monitoring participants to evaluate the drug’s safety profile and potential therapeutic effects over an extended period.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Progressive Supranuclear Palsy Pipeline Insight Report
- Which companies/institutions are leading the progressive supranuclear palsy drug development?
- Which company is leading the progressive supranuclear palsy pipeline development activities?
- What is the current progressive supranuclear palsy commercial assessment?
- What are the opportunities and challenges present in the Pprogressive supranuclear palsy pipeline landscape?
- What is the efficacy and safety profile of progressive supranuclear palsy pipeline drugs?
- Which company is conducting major trials for progressive supranuclear palsy drugs?
- Which companies/institutions are involved in progressive supranuclear palsy collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in progressive supranuclear palsy?
Reasons To Buy This Report
The Progressive Supranuclear Palsy Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for progressive supranuclear palsy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into progressive supranuclear palsy collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Parkinson’s Disease Drugs Market
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share